Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Dermatology Reports
Published in: Current Dermatology Reports 4/2023

30-08-2023 | Fingolimod | HOT TOPIC

Incidence and Characteristics of Melanoma in Multiple Sclerosis Patients Treated With Fingolimod: A Systematic Review

Authors: Melinda Jiang, Lydia Lam, YiZhong Zhuang, Rudy Goh, Joshua G. Kovoor, Aashray K. Gupta, William B. Smith, Mark Slee, Stephen Bacchi

Published in: Current Dermatology Reports | Issue 4/2023

Login to get access

Abstract

Purpose of Review

The treatment of multiple sclerosis has been revolutionised by disease-modifying therapies including fingolimod. However, these treatments are immunosuppressive and may be associated with increased risk and severity of skin cancer including melanoma. The aim of this review was to identify and evaluate the existing evidence regarding this relationship to help guide future patient counselling and screening practices. This systematic review involved a systematic search of the databases PubMed, EMBASE and Cochrane library, which was performed in July 2022.

Recent Findings

The initial search strategy identified 1,457 studies, of which 19 fulfilled the inclusion criteria totalling 20,175 patients receiving fingolimod. In total, there were 141 cases of melanoma reported in patients receiving fingolimod. The reported melanomas were all cutaneous, there were no new cases of uveal or genitourinary mucosal melanoma reported. It is unclear whether duration of treatment with fingolimod affects melanoma risk, severity, recurrence rates, metastatic potential or outcome. Patient-related risk factors such as skin type, UV exposure, family history etc. were not reported in most studies. In most reports, patients who developed melanoma discontinued fingolimod. There were no reports of metastatic disease or death.

Summary

Multiple case reports, observational studies, pharmacovigilance studies and clinical trials have reported melanoma in MS patients receiving fingolimod. This literature review provides evidence to support the recommendation of screening for melanoma in patients receiving fingolimod. Prior to the commencement of fingolimod, patients should be screened for melanoma risk factors and be counselled accordingly.
Appendix
Available only for authorised users
Literature
1.
2.
Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–15.CrossRefPubMed
3.
Alping P, Askling J, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Ann Neurol. 2020;87(5):688–99.CrossRefPubMed
4.
Manni A, Direnzo V, Iaffaldano A, Di Lecce V, Tortorella C, Zoccolella S, et al. Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort. Brain Behav. 2017;7(10): e00804.CrossRefPubMedPubMedCentral
5.
White C, Alshaker H, Cooper C, Winkler M, Pchejetski D. The emerging role of FTY720 (Fingolimod) in cancer treatment. Oncotarget. 2016;7(17):23106–27.CrossRefPubMedPubMedCentral
6.
Herzinger T, Kleuser B, Schäfer-Korting M, Korting HC. Sphingosine-1-Phosphate Signaling and the Skin. Am J Clin Dermatol. 2007;8(6):329–36.CrossRefPubMed
7.
Hasan Ali O, Berner F, Ackermann CJ, Ring SS, Moulin A, Müller J, et al. Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients. Cancer Immunology, Immunotherapy. 2021;70(2):563–8.CrossRefPubMed
8.
9.
Berge LAM, Andreassen BK, Stenehjem JS, Heir T, Karlstad Ø, Juzeniene A, et al. Use of Immunomodulating Drugs and Risk of Cutaneous Melanoma: A Nationwide Nested Case-Control Study</p&gt. Clinical Epidemiology. 2020;12:1389–401.CrossRefPubMedPubMedCentral
10.
Cordaro A, Dobbs TD, Gibson JA, Whitaker S, Whitaker IS. Skin cancer screening in organ transplant centres in the United Kingdom: a national survey. Eur J Dermatol. 2020;30(4):372–6.CrossRefPubMed
11.
Budde K, Schutz M, Glander P, Peters H, Waiser J, Liefeldt L, et al. FTY720 (fingolimod) in renal transplantation. Clin Transplant. 2006;20(Suppl 17):17–24.CrossRefPubMed
12.
Robinson CL, Guo M. Fingolimod (Gilenya) and melanoma. BMJ Case Rep. 2016;2016.
13.
Killestein J, Leurs CE, Hoogervorst ELJ, van Eijk J, Mostert JP, van den Eertwegh AJM, et al. Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS. Neurology. 2017;89(9):970–2.CrossRefPubMed
14.
Filoni A, Lospalluti L, Giudice G, Bonamonte D, Vestita M. Fingolimod and melanoma risk: is there sufficient evidence? Clin Exp Dermatol. 2017;42(4):427–8.CrossRefPubMed
15.
Haebich G, Mughal A, Tofazzal N. Superficial spreading malignant melanoma in a patient on fingolimod therapy for multiple sclerosis. Clin Exp Dermatol. 2016;41(4):433–4.CrossRefPubMed
16.
Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10023):1075–84.CrossRefPubMed
17.
Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401.CrossRefPubMed
18.
19.
Cohen JA, Khatri B, Barkhof F, Comi G, Hartung H-P, Montalban X, et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry. 2016;87(5):468-75.
20.
Kappos L, Li DK, Stuve O, Hartung HP, Freedman MS, Hemmer B, et al. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study. JAMA Neurol. 2016;73(9):1089–98.CrossRefPubMed
21.
Stamatellos VP, Rigas A, Stamoula E, Lallas A, Papadopoulou A, Papazisis G. S1P receptor modulators in Multiple Sclerosis: Detecting a potential skin cancer safety signal. Mult Scler Relat Disord. 2022;59: 103681.CrossRefPubMed
22.
23.
24.
Pašić A. Wolff K, Johnson RA, Suurmond D, eds. Fitzpatrick´ s Color Atlas and Synopsis of Clinical Dermatology. New York: McGraw-Hill, 2005. One volume. Pages 1085, parts four, sections 33. ISBN 0-07-144019-4. Acta Dermatovenerologica Croatica. 2007;15(3):0.
25.
Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372: n160.CrossRefPubMedPubMedCentral
26.
27.
Maniscalco GT, Morra VB, Florio C, Lus G, Tedeschi G, Cianfrani M, et al. Preliminary results of the FASM study, an on-going italian active pharmacovigilance project. Pharmaceuticals. 2020;13(12):1–18.CrossRef
28.
Montalban X, Comi G, Antel J, O’Connor P, De Vera A, Cremer M, et al. Long-term (>7-year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology. 2012;259(1 SUPPL. 1):S69–70.
29.
Velter C, Thomas M, Cavalcanti A, Bastien M, Chochon F, Lubetzki C, et al. Melanoma during fingolimod treatment for multiple sclerosis. Eur J Cancer. 2019;113:75–7.CrossRefPubMed
30.
Conzett KB, Kolm I, Jelcic I, Kamarachev J, Dummer R, Braun R, et al. Melanoma occurring during treatment with fingolimod for multiple sclerosis: a case report. Arch Dermatol. 2011;147(8):991–2.CrossRefPubMed
31.
Havla JB, Pellkofer HL, Meinl I, Gerdes LA, Hohlfeld R, Kümpfel T. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Arch Neurol. 2012;69(2):262–4.CrossRefPubMed
32.
Carbone ML, Lacal PM, Messinese S, De Giglio L, Pozzilli C, Persechino S, et al. Multiple Sclerosis Treatment and Melanoma Development. Int J Mol Sci. 2020;21(8).
33.
Michiels Y, Bugnon O, Michiels JF, Mazellier S. Detection of a new melanoma in a patient treated with fingolimod. BMJ Case Rep. 2019;12(4).
34.
35.
Norgaard M, Veres K, Didden EM, Wormser D, Magyari M. Multiple sclerosis and cancer incidence: A Danish nationwide cohort study. Mult Scler Relat Disord. 2019;28:81–5.CrossRefPubMed
36.
Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Sorensen PS, et al. A systematic review of the incidence and prevalence of cancer in multiple sclerosis. Multiple Sclerosis Journal. 2015;21(3):294–304.CrossRefPubMed
37.
Smith KJ, Hamza S, Skelton H. Histologic features in primary cutaneous squamous cell carcinomas in immunocompromised patients focusing on organ transplant patients. Dermatol Surg. 2004;30(4 Pt 2):634–41.PubMed
38.
Yamaguchi H, Kitayama J, Takuwa N, Arikawa K, Inoki I, Takehara K, et al. Sphingosine-1-phosphate receptor subtype-specific positive and negative regulation of Rac and haematogenous metastasis of melanoma cells. Biochem J. 2003;374(Pt 3):715–22.CrossRefPubMedPubMedCentral
39.
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer Today. [homepage on the internet] Lyon, France: International Agency for Research on Cancer; 2020 [cited 2022 Jul 20]. Available from: https://​gco.​iarc.​fr/​today.
40.
Novartis Pharmaceuticals UK Ltd. Gilenya, INN-fingolimod Summary of Product Characteristics. Access date: 07/01/23.
41.
Barbieri MA, Sorbara EE, Battaglia A, Cicala G, Rizzo V, Spina E, et al. Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database. Front Pharmacol. 2022;13: 808370.CrossRefPubMedPubMedCentral
Metadata
Title
Incidence and Characteristics of Melanoma in Multiple Sclerosis Patients Treated With Fingolimod: A Systematic Review
Authors
Melinda Jiang
Lydia Lam
YiZhong Zhuang
Rudy Goh
Joshua G. Kovoor
Aashray K. Gupta
William B. Smith
Mark Slee
Stephen Bacchi
Publication date
30-08-2023
Publisher
Springer US
Published in
Current Dermatology Reports / Issue 4/2023
Electronic ISSN: 2162-4933
DOI
https://doi.org/10.1007/s13671-023-00400-0

Other articles of this Issue 4/2023

Current Dermatology Reports 4/2023 Go to the issue

REVIEW

The Role of Dermoscopy in Provider-to-Provider Store-and-Forward Dermatology eConsults: A Scoping Review of the Recent Literature

REVIEW

Inpatient Evaluation and Management of Generalized Pustular Dermatoses

REVIEW

Patch Testing in Atopic Children: Is There a Difference?

REVIEW

Immune Checkpoint Inhibitors and Systemic Side Effects: Overview for the Inpatient Dermatologist

REVIEW

The Future of Patch Testing: Reimbursement Models, Workforce Shortages, and Negotiating in the House of Medicine

REVIEW

The Safety and Accuracy of Drug Patch Testing in Delayed Hypersensitivity Reactions